United States · Platforms & data · TipRanks

Cantargia Reports Early Nadunolimab Responses in MDS and AML

Published by TipRanks · United States 9 h ago

Nadunolimab combinations produced responses in MDS and AML. Limited treatment-related severe toxicity supported nadunolimab’s early profile. Looking for the best stocks to buy?…

Read the full article on TipRanks Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.tipranks.com)

Also worth reading

The Motley Fool

AI Regulation Was on the Ballot In These States. Here Are The Elon Musk Stocks That Could Be Impacted.

MarketBeat

Wells Fargo & Company Forecasts Strong Price Appreciation for American Well (NYSE:AMWL) Stock

Seeking Alpha

IREN Q1 earnings on deck: what to expect

MarketWatch

Depressing, but true: If you want to get ahead at work, embrace virtue signaling

CNBC

10-year Treasury yield is little changed as traders mull over Democrats' midterm victories

Benzinga